• Proceedings of the Korean Nuclear Society Conference
• /
• 2001.10a
• /
• pp.319.2-319
• /
• 2001

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.6 no.1
• /
• pp.10-19
• /
• 2020

Boron Neutron Capture Therapy (BNCT) has the advantage of selectively removing cancer cells ingesting boron compounds. In this study, the benefits for treatment time and boron compound injection dose were compared between current neutron sources and a high current neutron sources to be developed in near future. The time-activity curve (TAC) of GBM (Glioblastoma) for one bolus injection was obtained by applying modified 3 compartment model. The treatment time was determined for an accelerator-based neutron sources at the present time and a high current accelerator based neutron source to be developed in the near future. In the case of the double amount of IAEA-recommended neutron flux, the treatment time was shortened to 15 minutes. In the case of high current accelerators, which are five times the amount of IAEA-recommended neutron flux, the irradiation time is within 5 minutes. The use of a high current accelerator based neutron source in BNCT is advantageous in terms of treatment time. In addition, it can increase the efficiency of use of neutrons and reduce the boron compound injection dose to patients, thus reducing pharmacological toxicity.